louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00628823: Treatment of Mild Enteropathy Celiac Disease
Official title: Treatment of Mild Enteropathy Celiac Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Celiac Disease
Keywords: Celiac Disease
Endomysial antibodies
Mild enteropathy
Treatment
Gluten-free diet
Lead sponsor: Tampere University Hospital
Sponsor class: OTHER
Collaborators: name: Academy of Finland
name: Tampere University
First posted: 2008-03-05
Enrollment: 73
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main purpose of this study is to evaluate the natural history of gluten sensitivity in endomysial antibody positive adults with celiac disease suspicion, who were found to have a only mild enteropathy (Marsh I-II) in the small-bowel mucosa. The investigators hypothesize that these subject are indeed gluten-sensitive, as measured by clinical, serological and histological indicators. If this would be the case, the current diagnostic criteria for celiac disease might need re-evaluation.

Detailed description: The current diagnostic criteria of celiac disease require small-bowel mucosal villous atrophy with crypt hyperplasia (Marsh III). However, the mucosal damage develops gradually and the patients may have clinical symptoms and endomysial antibodies before the development of villous atrophy.

The main purpose of this study is to evaluate the natural history of gluten sensitivity in endomysial antibody positive adults with celiac disease suspicion, who were found to have a only mild enteropathy (Marsh I-II) in the small-bowel mucosa. We hypothesize that these subject are indeed gluten-sensitive, as measured by clinical, serological and histological indicators. If this would be the case, the current diagnostic criteria for celiac disease might need re-evaluation.

Eligibility criteria: Inclusion Criteria:

* Celiac disease suspicion
* Positive endomysial antibodies
* At least Marsh I -type small-bowel mucosal lesion

Exclusion Criteria:

* Earlier celiac disease diagnosis
* Consuming oral corticosteroids or immune suppressants

Primary outcomes:
measure: Small-Bowel mucosal morphology
timeFrame: one year
Secondary outcomes:
measure: Endomysial antibodies, tissue transglutaminase antibodies, Small-Bowel mucosal inflammation, clinical symptoms, laboratory parameters, bone mineral density.
timeFrame: One year
Other outcomes:
Locations:
city: Tampere
country: Finland
facility: University of Tampere
Study officials:
affiliation: Tampere University
name: Katri Kaukinen, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00487123: Efficacy of the New Closure Device in Improving Patient Compliance in Treatment of Hypertension With Valsartan+/-Hydrochlorothiazide (HCTZ) at 6 Months
Official title: A Multi-Center, Randomized, Proof-of-Concept, Parallel Control Study With Remind Cap® in Patients With Essential Hypertension and Newly Treated With Valsartan+/-Hydrochlorothiazide (HCTZ)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hypertension
Keywords: Hypertension, compliance, Valsartan, hydrochlorothiazide (HCTZ)
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2007-06-15
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will evaluate the efficacy of the reminder device Remind Cap® in improving patients' compliance in the consumption of Valsartan +/- Hydrochlorothiazide (HCTZ) in the treatment of hypertension


Eligibility criteria: Inclusion Criteria:

* Patients with hypertension that have newly started using Valsartan+/-HCTZ

Exclusion Criteria:

* Pregnancy or Hypersensitivity to Valsartan+/-HCTZ

Other protocol-defined inclusion/exclusion criteria may apply

Primary outcomes:
measure: Compliance rate at month 3, 6 and post study month 1 will be assessed by pill count
Secondary outcomes:
measure: Patient Adherence to study/follow up visits -Clinical Outcome Measurement: Mean sitting systolic BP and mean sitting diastolic BP -Patient's and Physician's Satisfaction Survey
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: Novartis Investigative Site
Study officials:
affiliation: Sponsor GmbH
name: non IND
role: STUDY_CHAIR
References:
Clinical trial NCT04418323: Video-assisted Anal Fistula Treatment (VAAFT) Versus Fistula-tract Laser Closure (Filac) Versus Conventional Seton in the Management of Anal Fistula
Official title: Video-assisted Anal Fistula Treatment (VAAFT) Versus Fistula-tract Laser Closure (Filac) Versus Conventional Seton in the Management of Anal Fistula
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Video Assisted Anal Fistula Treatment
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2020-06-05
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Anal fistula is a chronic inflammatory tract connecting an internal opening in the anal canal with one or more than one external openings in the perianal skin Aim of the work This prospective randomized control trial, we will compare video-assisted anal fistula treatment (Vaaft) and Fistula Laser closure (Filac) and conventional Seton as regards, recurrence rate as a primary outcome. Secondary outcome includes; operative and post-operative data, hospital stay, pain score, healing time, return to work and continence


Eligibility criteria: Inclusion Criteria:

* Patients of both genders aging between 18-65 years with cryptoglandular anal fistula will be included.

Exclusion Criteria:

* We will exclude patients with associated anorectal pathology such as anal fissure, hemorrhoids, rectal prolapse, neoplasm, solitary rectal ulcer, inflammatory bowel diseases, and patients on long acting corticosteroids or immunosuppressive drugs will be also excluded.

Primary outcomes:
measure: recurrence of anal fistula
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Mansoura
country: Egypt
facility: Mansoura University
state: Dakahlia
Study officials:
References:
Clinical trial NCT05304923: Supraglottic Jet Oxygenation and Ventilation for Gastrointestinal Endoscopy at High-altitude
Official title: Supraglottic Jet Oxygenation and Ventilation (SJOV) for Hypoxemia During Deep Sedation for Gastrointestinal Endoscopy at High-altitude
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Hypoxia
High Altitude
Lead sponsor: Peking University People's Hospital
Sponsor class: OTHER
Collaborators: name: Tibet Autonomous Region People's Hospital
First posted: 2022-03-31
Enrollment: 72
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study aims to determine whether the use of SOJV could reduce the rate of hypoxia during gastrointestinal endoscopic procedures in deeply sedated patients sedated at high altitude comparing to the supplemental oxygen administration via nasal cannula.

Detailed description: The participants will be randomly allocated to either SJOV or nasal cannula oxygen supply in a 1:1 ratio using block randomization with variable block sizes of four or six randomized. In the nasal cannula oxygen supply group, oxygen supplementation at 2 liters min-1 is delivered via a nasal cannula. In the SJOV group, SJOV is conducted using a Wei nasal jet tube (WNJ, Well Lead Medical Co. Ltd, Guangzhou, China) which is connected to a manual jet ventilator (Well Lead Medical Co. Ltd, Guangzhou, China) via its jet port.

Eligibility criteria: Inclusion Criteria:

1. 18 years or older;
2. underwent routine gastrointestinal endoscopy under procedural sedation;
3. consented to participate in this trial. -

Exclusion Criteria:

1. infection of the upper airway;
2. anatomical abnormalities of the face, nose, and upper airway;
3. coagulopathies;
4. anticipated or known difficult airway;
5. known allergy against propofol, soybeans, and egg;
6. absence from the high-altitude environment during the past 3 months. -

Primary outcomes:
measure: Hypoxia during sedation
timeFrame: During sedation procedure
Secondary outcomes:
measure: respiratory-related complications
timeFrame: During sedation procedure
measure: cardiovascular-related complications
timeFrame: During sedation procedure
measure: fatal complications
timeFrame: from sedation initiation to 20 min after patients are awake
Other outcomes:
measure: Adverse events related to Supraglottic Jet Oxygenation and Ventilation
timeFrame: 20 min after patients are awake
Locations:
city: Lhasa
country: China
facility: Tibet autonomous region people's hospital
state: Tibet
Study officials:
affiliation: Peking University People's Hospital
name: Yi Feng
role: PRINCIPAL_INVESTIGATOR
References:
citation: Jiang B, Li Y, Ciren D, Dawa O, Feng Y, Laba C. Supraglottic jet oxygenation and ventilation decreased hypoxemia during gastrointestinal endoscopy under deep sedation at high altitudes: a randomized clinical trial. BMC Anesthesiol. 2022 Nov 14;22(1):348. doi: 10.1186/s12871-022-01902-3.
Clinical trial NCT01134523: Regimens Comparison for Breast Cancers of Positive Lymph Nodes
Official title: Phase 3 Study of Regimens Comparison for Breast Cancers of Positive Lymph Nodes
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Breast Cancer
Keywords: positive lymph node
Lead sponsor: ChineseAMS
Sponsor class: UNKNOWN
First posted: 2010-06-02
Enrollment: 1000
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare the efficacy and safety of EC-T and ET regimen as adjuvant treatment of breast cancer patients with positive lymph nodes

Detailed description: EC-T regimen: epirubicin 90mg/m2 day1, CTX 600mg/m2, day 1, 21 days per cycle \*4cycle. followed by paclitaxel 175mg/m2,d1,21days per cycle, 4 cycle.

ET regimen: epirubicin 75mg/m2 day1,paclitaxel 175mg/m2,d2,21days per cycle, 6 cycle

Eligibility criteria: Inclusion Criteria:

* patients with breast cancer after breast cancer surgery with positive lymph nodes age 18-70 years old

Exclusion Criteria:

* with other malignance disease

Primary outcomes:
measure: PFS
timeFrame: 5 years after all the recuiment
Secondary outcomes:
measure: OS
timeFrame: 5 years after all the adjuvent treatments
measure: Safety
timeFrame: 5 years after all the recruiment
Other outcomes:
Locations:
city: Beijing
country: China
facility: Cancer Institute & Hospital. Chinese Academy of Medical Sciences
Study officials:
affiliation: Chinese Academy of Medical Sciences
name: Binghe Xu, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Moebus V, Jackisch C, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Schneeweiss A, Huober J, Harbeck N, von Minckwitz G, Runnebaum IB, Hinke A, Kreienberg R, Konecny GE, Untch M. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol. 2010 Jun 10;28(17):2874-80. doi: 10.1200/JCO.2009.24.7643. Epub 2010 May 10.
Clinical trial NCT00166023: Outcomes Following Medical or Surgical Management of Endocarditis
Official title: A Review of Outcomes Following Medical or Surgical Management of Endocarditis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Endocarditis
Keywords: pediatric
cardiology
Lead sponsor: Emory University
Sponsor class: OTHER
First posted: 2005-09-14
Enrollment: 100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no

Brief summary: Infective endocarditis is a rare disease, and while there have been several large reviews of the incidence of endocarditis in the pediatric patient population, relatively little has been published regarding the short and medium-term outcomes following medical and surgical therapy for this disease. The goal is to compare the outcome for children treated for endocarditis with either medical management or surgery by looking at the success of these two treatment strategies. Another goal is to attempt to identify risk factors for medical management that might identify patients who would be better served by early surgery.

Detailed description: After identification of qualified subjects, the families of surviving patients will be mailed a package containing a cover letter explaining the study, a consent form, an assent form if applicable, a questionnaire (designed to evaluate longer-term outcome measures including the occurrence of recurrent endocarditis, late surgical intervention or the need for re-operations) and a self addressed stamped envelope to be used to return the consents and the questionnaire. The data will then be entered into a database and analyzed.

Eligibility criteria: Inclusion Criteria:

* All patients discharged from Children's Healthcare of Atlanta at Egleston with a discharge diagnosis of endocarditis or those who underwent surgery with a preoperative diagnosis of endocarditis.
* Admitted to the hospital between January 1, 1984 - December 31, 2004, inclusive.
* Signed informed consent.

Exclusion Criteria:

* Patients who do not have documented endocarditis based upon microbiology and echocardiography criteria.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Children's Healthcare of Atlanta
state: Georgia
Study officials:
affiliation: Emory University
name: Paul Kirshbom, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05639023: Orthopaedic Manipulation in Treatment of Adolescent Idiopathic Scoliosis
Official title: The Orthopaedic Manipulation Techniques of the Lin School of Lingnan Region in the Treatment of Adolescent Idiopathic Scoliosis - A Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Adolescent Idiopathic Scoliosis
Lead sponsor: Chinese University of Hong Kong
Sponsor class: OTHER
First posted: 2022-12-06
Enrollment: 50
Sex: ALL
Minimum age (years): 10
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To examine the clinical efficacy of the Orthopaedic Manipulation Techniques of the Lin School of Lingnan Region in the treatment of Adolescent Idiopathic Scoliosis

Detailed description: After being informed about the study and potential risk, all patients giving written informed consent will undergo a 0-week screening period to determine eligibility for study entry. At week 0, patients who meet the eligibility requirements will be randomized in a single-blind manner(participant) in a 1:1 ratio to Manipulation Techniques Group or Control Group.

Eligibility criteria: Inclusion Criteria:

1. Adolescents aged between 10 and 18 who can speak and read Chinese
2. Fulfil the diagnostic criteria of scoliosis, i.e. Cobb's angle ≥ 10 degree
3. Risser grade ranging from 0 to 4
4. Informed consent agreement signed by both subject and their parents/guardians
5. Able to participate in follow-up assessments

Exclusion Criteria:

1. History of spine surgery;
2. Cobb's angle \>30 degrees
3. Known to have severe respiratory or cardiovascular comorbidities; vertebral tumours and spinal canal abnormalities; Leukaemia, thrombocytopenia and other bleeding disorders
4. Known to have cognitive impairment.
5. Documented pregnancy
6. Wearing brace within 1 month.
7. Involved in other interventional clinical studies at the same time.
8. Uncooperative during treatments
9. Being assessed by investigators as unsuitable to participate.

Primary outcomes:
measure: Change of Scoliosis Research Society-22 (SRS-22)
timeFrame: Baseline, Week 8,16,24
Secondary outcomes:
measure: Change of Traditional Chinese version of Spinal Appearance Questionnaire score (TC-SAQ)
timeFrame: Baseline, Week 8,16,24
measure: Change of Cobb's angle measured by Xray
timeFrame: Baseline, Week 16
measure: Change of spinal rotation by Ultrasonography
timeFrame: Before and after the manipulation with the duration of 16 weeks
measure: Change of muscle volume by Ultrasonography
timeFrame: Before and after every manipulation with the treatment duration of 16 weeks
measure: Change of Cobb's angle measured by Ultrasonography
timeFrame: Before and after the manipulation with the duration of 16 weeks
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02344823: Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis
Official title: Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Cirrhosis
Erectile Dysfunction
Keywords: cirrhosis
erectile dysfunction
portal hypertension
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2015-01-26
Enrollment: 30
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators want to analyze the effect of Vardenafil on Erectile Dysfunstion and portal hemodynamics in patients with liver cirrhosis.

Detailed description: 2 Phase 2 arm study

Phase A:

Baseline HVPG (Hepatic Venous Pressure Measurement) measurement, followed by 1 capsule of 10mg Vardenafil or Placebo (randomization 1:1) daily per oral for 7 days, HVPG measurement at day 7

Phase B:

1 capsule of 10mg Vardenafil or Placebo (randomization 1:1) ad libidum per oral for 28 days

Eligibility criteria: Inclusion Criteria:

* Male patients aged older than 18 years with mild to moderate (Child´s Grade A or B) cirrhosis scheduled for hepatic hemodynamic investigation.
* Erectile dysfunction in medical history
* Following beta-blocker therapy will be allowed: carvedilol (up to the max. dose of 25 mg) and propranolol (up to the max. dose of 160 mg)
* Patient living in a stable relationship
* HVPG (Hepatic Venous Pressure Measurement)\>= 10 mmHg

Exclusion Criteria:

* HVPG \<10
* HVPG \> 20 mmHg and varices, unless ligated and treated in an eradication program within 6 months
* history of variceal bleeding without secondary prophylaxis with beta blocker or endoscopic band ligation
* History of endoscopically diagnosed large varices with red spots without previous bleeding and without prophylactic beta blocker or endoscopic band ligation
* History of hypersensitivity to the trial drugs and contrast agent or to drugs with a similar chemical structure
* Treatment with vasoactive or non-steroidal anti-inflammatory drugs or systemic antibiotics one week before the study
* Exclusion criteras for hepatic hemodynamic investigation
* Cardiac, renal or respiratory failure
* previous surgical or transjugular intrahepatic portosystemic shunt
* insulin-dependent diabetes
* Child´s Grade C cirrhosis

Primary outcomes:
measure: HVPG (Hepatic Venous Pressure Measurement)
timeFrame: 7 days
measure: IIEF (International Index of Erectile Function ) 5
timeFrame: 28 days
Secondary outcomes:
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Dept. of Internal Medicine III, Gastroenterology and Hepatology, Medical University of Vienna
Study officials:
affiliation: Medical University of Vienna
name: Arnulf Ferlitsch, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00328523: TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060)
Official title: Ezetimibe Together With Any Statin Cholesterol Enhancement
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Hypercholesterolaemia
Hyperlipidaemia
Lead sponsor: Organon and Co
Sponsor class: INDUSTRY
First posted: 2006-05-22
Enrollment: 1496
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In patients with primary hypercholesterolemia treated with a statin and with ldl-c above the recommended target goal (esc 2003 recommendations ldl\>=1.15 g/l) to compare the efficacy and the safety of ezetrol added to ongoing statin and non drug therapeutic intervention (patient motivation on diet or physical activities or both).


Eligibility criteria: Inclusion Criteria:

* Primary hypercholesterolemia treated with any statin at any dose, for at least 3 months with a ldl cholesterol above 115 mg/dl (esc 2003 recommendations).

Exclusion Criteria:

* pregnant or breast feeding women
* Lipid-lowering agents including hmg-coa reductase inhibitors other than the current statin, fish oils, cholestyramin, niacin (\>200 mg/day) and fibrates taken within the 3 months preceding visit 1.

Primary outcomes:
measure: Percent of patients attaining the ldl cholesterol target goal based on the lipids result at the end of the study (3 months).
Secondary outcomes:
measure: Treatment with ezetimibe 10 mg/day will be well tolerated and no difference in tolerance will be shown between the 3 treatment groups.
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Steg PG, Verdier JC, Carre F, Darne B, Ducardonnet A, Jullien G, Farnier M, Giral P, Haiat R; TWICE Investigators, France. A randomised trial of three counselling strategies for lifestyle changes in patients with hypercholesterolemia treated with ezetimibe on top of statin therapy (TWICE). Arch Cardiovasc Dis. 2008 Nov-Dec;101(11-12):723-35. doi: 10.1016/j.acvd.2008.10.008. Epub 2008 Nov 20.
Clinical trial NCT02381223: Simplified Medical Abortion Screening: A Pilot Demonstration Project
Official title: Simplified Medical Abortion Screening: A Pilot Demonstration Project
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Medical; Abortion, Fetus
Lead sponsor: Gynuity Health Projects
Sponsor class: OTHER
First posted: 2015-03-06
Enrollment: 409
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Female: only female participants are being studied

Brief summary: This study aims to collection additional data on the safety and acceptability of medical abortion without pretreatment pelvic ultrasound or exam in woman who meet certain criteria.


Eligibility criteria: Inclusion criteria:

* Women having medical abortion

Primary outcomes:
measure: Incidence of serious adverse events
timeFrame: 7 days
Secondary outcomes:
Other outcomes:
Locations:
city: Friendship Heights
country: United States
facility: Carafem
state: Maryland
city: Minneapolis
country: United States
facility: Planned Parenthood Minnesota, North Dakota, South Dakora
state: Minnesota
city: New York
country: United States
facility: Institute for Family Health
state: New York
city: Mexico Distrito Federal
country: Mexico
facility: Centro de Salud Mexico-Espana
city: Chisinau
country: Moldova, Republic of
facility: Reproductive Health Training Center
Study officials:
affiliation: Gynuity Health Projects
name: Elizabeth Raymond, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Raymond EG, Tan YL, Comendant R, Sagaidac I, Hodorogea S, Grant M, Sanhueza P, Van Pratt E, Gillespie G, Boraas C, Weaver MA, Platais I, Bousieguez M, Winikoff B. Simplified medical abortion screening: a demonstration project. Contraception. 2018 Apr;97(4):292-296. doi: 10.1016/j.contraception.2017.11.005. Epub 2017 Nov 21.